THE WOODLANDS, Texas,
May 3, 2013 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a
biopharmaceutical company focused on discovering breakthrough
treatments for human disease, will release its first quarter 2013
financial results on Friday, May 10,
2013 before the financial markets open. Lexicon
management will hold a conference call and webcast to discuss
clinical development progress and financial results for the first
quarter at 11:00 a.m. Eastern Time on
May 10, 2013.
The dial-in number for the conference call is 888-645-5785
(within the US/Canada) or
970-300-1531 (international). The conference ID for all
callers is 64449185. Investors can access a live webcast of
the call at www.lexpharma.com. An archived version of the
webcast will be available on the website through June 10, 2013.
About Lexicon
Lexicon is a biopharmaceutical company
focused on discovering breakthrough treatments for human
disease. Lexicon currently has multiple drug programs in
clinical development for diabetes, irritable bowel syndrome,
carcinoid syndrome and other indications, all of which were
discovered by Lexicon's research team. Lexicon has used its
proprietary gene knockout technology to identify more than 100
promising drug targets. Lexicon has focused drug discovery
efforts on these biologically-validated targets to create its
extensive pipeline of clinical and preclinical programs. For
additional information about Lexicon and its programs, please visit
www.lexpharma.com.
Safe Harbor Statement
This press release contains
"forward-looking statements," including statements
relating to Lexicon's growth and future operating results,
discovery and development of products, strategic alliances and
intellectual property, as well as other matters that are not
historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2012, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.